CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Rating of "Hold" from Brokerages

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have been assigned a consensus rating of "Hold" from the five analysts that are presently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $6.53.

Several equities research analysts recently commented on CTMX shares. HC Wainwright restated a "neutral" rating on shares of CytomX Therapeutics in a research report on Thursday. JPMorgan Chase & Co. raised shares of CytomX Therapeutics from an "underweight" rating to a "neutral" rating in a research note on Monday, April 22nd. BMO Capital Markets upped their price objective on shares of CytomX Therapeutics from $3.25 to $3.59 and gave the company a "market perform" rating in a report on Thursday. Wedbush upgraded CytomX Therapeutics from a "neutral" rating to an "outperform" rating and raised their target price for the company from $3.00 to $8.00 in a research note on Thursday. Finally, Jefferies Financial Group raised CytomX Therapeutics from a "hold" rating to a "buy" rating and upped their price target for the stock from $2.50 to $8.00 in a research note on Monday.

CytomX Therapeutics Stock Performance

CTMX traded down $2.15 during trading hours on Thursday, reaching $2.04. The company's stock had a trading volume of 40,496,738 shares, compared to its average volume of 4,348,851. The company's 50-day moving average is $2.38 and its 200-day moving average is $1.78. CytomX Therapeutics has a 52 week low of $1.04 and a 52 week high of $5.85. The firm has a market cap of $139.00 million, a PE ratio of -117.50 and a beta of 1.09.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last released its quarterly earnings results on Monday, March 11th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.01). The company had revenue of $26.61 million during the quarter, compared to analyst estimates of $23.36 million. Equities analysts anticipate that CytomX Therapeutics will post -0.25 earnings per share for the current fiscal year.

Insider Transactions at CytomX Therapeutics

In related news, CEO Sean A. Mccarthy sold 20,223 shares of CytomX Therapeutics stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $2.09, for a total value of $42,266.07. Following the transaction, the chief executive officer now owns 524,481 shares in the company, valued at approximately $1,096,165.29. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders sold 35,024 shares of company stock valued at $73,200. 7.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. AlphaMark Advisors LLC boosted its holdings in shares of CytomX Therapeutics by 119.8% during the 4th quarter. AlphaMark Advisors LLC now owns 23,183 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 12,635 shares during the last quarter. SG Americas Securities LLC bought a new stake in CytomX Therapeutics in the 1st quarter worth approximately $57,000. Susquehanna Fundamental Investments LLC bought a new position in shares of CytomX Therapeutics during the 1st quarter valued at $124,000. Congress Park Capital LLC boosted its stake in shares of CytomX Therapeutics by 112.8% in the 4th quarter. Congress Park Capital LLC now owns 239,300 shares of the biotechnology company's stock worth $371,000 after buying an additional 126,850 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of CytomX Therapeutics by 737.4% in the third quarter. Bank of New York Mellon Corp now owns 266,836 shares of the biotechnology company's stock worth $344,000 after acquiring an additional 234,970 shares during the period. Hedge funds and other institutional investors own 67.77% of the company's stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.